Product
CHOP+X
1 clinical trial
1 indication
Indication
Peripheral T-cell LymphomaClinical trial
The Efficacy and Safety of Targeted Drug in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Newly Diagnosed Peripheral T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-04-20